: In this issue, B. Gaglani, T. M. Andermann, C. Wate, J. Oldan, et al. (Antimicrob Agents Chemother 70:e01542-25, 2026, https://doi.org/10.1128/aac.01542-25) describe a recurrent Burkholderia cenocepacia infection successfully treated with cefiderocol plus sulbactam-durlobactam. Treatment decisions are often made with incomplete microbiological and pharmacological data, even as interest in mechanism-based β-lactam combination strategies continues to grow. This case supports the utility of cefiderocol plus sulbactam-durlobactam in B. cenocepacia infection and reinforces the importance of multidisciplinary approaches to better estimate the risk of treatment failure and optimize antimicrobial therapy.
Case Commentary: When susceptibility is not enough in recurrent Burkholderia cenocepacia infection
Gaibani, Paolo
;
2026-01-01
Abstract
: In this issue, B. Gaglani, T. M. Andermann, C. Wate, J. Oldan, et al. (Antimicrob Agents Chemother 70:e01542-25, 2026, https://doi.org/10.1128/aac.01542-25) describe a recurrent Burkholderia cenocepacia infection successfully treated with cefiderocol plus sulbactam-durlobactam. Treatment decisions are often made with incomplete microbiological and pharmacological data, even as interest in mechanism-based β-lactam combination strategies continues to grow. This case supports the utility of cefiderocol plus sulbactam-durlobactam in B. cenocepacia infection and reinforces the importance of multidisciplinary approaches to better estimate the risk of treatment failure and optimize antimicrobial therapy.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
